Ratings Inspiration Healthcare Group plc

Equities

IHC

GB00BXDZL105

Market Closed - London S.E. Other stock markets 11:35:05 2024-05-17 am EDT			5-day change	1st Jan Change
16.25 ^GBX	+0.93%		+1.56%	-59.38%

May. 01	Inspiration Healthcare shares dive as awaits export order	AN
May. 01	AIM WINNERS & LOSERS: Trinity up after agreeing to Touchstone takeover	AN

Strengths

The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.64 for the 2024 fiscal year.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
INSPIRATION HEALTHCARE GROUP PLC	-59.38%	14.04M	-
SHOCKWAVE MEDICAL, INC.	+73.33%	12.42B	B-
PENUMBRA, INC.	-19.75%	7.81B	C+
MASIMO CORPORATION	+4.61%	6.4B	C-
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+13.24%	5.45B	D+
APT MEDICAL INC.	+38.48%	5.01B	-
GETINGE AB	-17.30%	4.84B	B
ASAHI INTECC CO., LTD.	-19.78%	4.19B	B-
INARI MEDICAL, INC.	-28.99%	2.69B	C
NOVOCURE LIMITED	+47.72%	2.39B	C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes